[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

August 2019 - April 2016

Decade

Year

Issue

September 2017, Vol 2, No. 9, Pages 933-1050

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):933. doi:10.1001/jamacardio.2016.3664
Original Investigation

Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial

Abstract Full Text
free access has audio
JAMA Cardiol. 2017;2(9):950-958. doi:10.1001/jamacardio.2017.2198

This randomized clinical trial analyzes the effects of high-dose spironolactone vs usual care on N-terminal pro-B-type natriuretic peptide levels.

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

Abstract Full Text
open access
JAMA Cardiol. 2017;2(9):959-966. doi:10.1001/jamacardio.2017.2289

This simulation model study estimates the percentage of patients with atherosclerotic cardiovascular disease who would require proprotein convertase subtilisin/kexin type 9 inhibitor therapy when oral therapy to lower lipid levels is intensified first.

Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):967-975. doi:10.1001/jamacardio.2017.2180

This study using data recorded in the Veterans Affairs Clinical Assessment, Reporting, and Tracking System for Cath Labs (CART-CL) program compares outcomes between black and white patients undergoing percutaneous coronary intervention in the Veterans Affairs hospitals system.

Temporal Changes in the Racial Gap in Survival After In-Hospital Cardiac Arrest

Abstract Full Text
free access has audio
JAMA Cardiol. 2017;2(9):976-984. doi:10.1001/jamacardio.2017.2403

This study examines whether racial differences in survival after in-hospital cardiac arrest have changed over time and whether these differences could be explained by acute resuscitation survival, postresuscitation survival, and/or greater temporal improvement in survival at hospitals with higher proportions of black patients.

Association of Coronary Artery Calcium Score vs Age With Cardiovascular Risk in Older Adults: An Analysis of Pooled Population-Based Studies

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):986-994. doi:10.1001/jamacardio.2017.2498

This study examines the predictive ability of coronary artery calcium score vs age for incident atherosclerotic cardiovascular disease and how risk prediction changes by adding coronary artery calcium score and removing only age from prediction models.

Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):995-1006. doi:10.1001/jamacardio.2017.2511

This cohort study investigates whether myocardial fibrosis is similarly prevalent in both those with heart failure with preserved ejection fraction (HFpEF) and those at risk for HFpEF, similarly associating with disease severity and outcomes.

Brief Report

Association of Variation in Contrast Volume With Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):1007-1012. doi:10.1001/jamacardio.2017.2156

This cross-sectional study uses NCDR CathPCI Registry data to examine the variation in contrast volume and acute kidney injury incidence among physicians who perform percutaneous coronary intervention.

Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):1013-1018. doi:10.1001/jamacardio.2017.1213

This cohort study investigates the association between change in skin disease severity and change in vascular inflammation at 1 year and characterizes the impact of 1 year of anti–tumor necrosis factor therapy on vascular inflammation in patients with psoriasis.

Association of Changes in Medication Use and Adherence With Accountable Care Organization Exposure in Patients With Cardiovascular Disease or Diabetes

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):1019-1023. doi:10.1001/jamacardio.2017.2172

This population-based study examines the use of and adherence to drugs from classes commonly used for therapy in patients with cardiovascular disease and diabetes.

Research Letter

Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):1040-1042. doi:10.1001/jamacardio.2017.2369

This population-based study uses the Acute Coronary Treatment and Intervention Outcomes Network Registry to evaluate the prevalence of smoking cessation medication use among patients following myocardial infarction.

Association Between Administration of Ticagrelor and Microvascular Endothelial Function

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):1042-1044. doi:10.1001/jamacardio.2017.2378

This clinical trial assesses ticagrelor administration and endothelial function and arterial stiffness in patients with coronary artery disease.

Viewpoint

Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era: Getting Back on Target

Abstract Full Text
JAMA Cardiol. 2017;2(9):935-936. doi:10.1001/jamacardio.2017.2293

This Viewpoint summarizes treatment options for lowering low-density lipoprotein cholesterol levels, specifically the effects of adding additional drugs to statin therapy.

Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?

Abstract Full Text
JAMA Cardiol. 2017;2(9):937-938. doi:10.1001/jamacardio.2017.2288

This Viewpoint summarizes the debate surrounding the LDL hypothesis and suggests next steps for better reducing atherosclerotic cardiovascular disease risk.

The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure

Abstract Full Text
JAMA Cardiol. 2017;2(9):939-940. doi:10.1001/jamacardio.2017.1891

This Viewpoint discusses the outcomes of the Empagliflozin Removal of Excess of Glucose Outcome trial and the optential benefits of sodium-dependent glucose cotransporter 2 in treating heart failure.

From the Heart

Reflections on Admissions for Heart—and Social System—Failure

Abstract Full Text
JAMA Cardiol. 2017;2(9):948-949. doi:10.1001/jamacardio.2017.1492
Editorial

Healthful Physical Activity and Diet Promotion—For the Many or the Few?

Abstract Full Text
JAMA Cardiol. 2017;2(9):941-943. doi:10.1001/jamacardio.2017.2568

This Editorial suggests that although the USPSTF awarded a C recommendation for the practice of behavioral counselling to promote healthful diet and physical activity for individuals at low risk for cardiovascular disease, such patient advice nonetheless has a good risk-benefit ratio.

Skin and Vascular Disease—Inside-Out/Outside-In

Abstract Full Text
JAMA Cardiol. 2017;2(9):944-945. doi:10.1001/jamacardio.2017.1420

Defining Potential Use of Nonstatin Therapies to Lower Blood Cholesterol Levels

Abstract Full Text
JAMA Cardiol. 2017;2(9):946-947. doi:10.1001/jamacardio.2017.2290
Invited Commentary

Racial Differences in In-Hospital Cardiac Arrest: Good News: Cautious Optimism Is Welcome

Abstract Full Text
has audio
JAMA Cardiol. 2017;2(9):984-985. doi:10.1001/jamacardio.2017.2432

Improving Care in an Accountable Care Organization: So Many Choices, So Little Time

Abstract Full Text
JAMA Cardiol. 2017;2(9):1023-1024. doi:10.1001/jamacardio.2017.2207
Special Communication

Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action

Abstract Full Text
has active quiz
JAMA Cardiol. 2017;2(9):1025-1029. doi:10.1001/jamacardio.2017.2275

This Special Communication examines the results of clinical trials to determine the benefit of sodium-glucose cotransporter 2 inhibitors on heart failure among patients with diabetes.

Review

Optimal Medical Therapy for Known Coronary Artery Disease: A Review

Abstract Full Text
JAMA Cardiol. 2017;2(9):1030-1035. doi:10.1001/jamacardio.2017.2249

This review examines optimal medical therapy as secondary prevention for patients with known coronary artery disease.

JAMA Cardiology Clinical Challenge

Arrhythmia in Bone Marrow Transplant Unit

Abstract Full Text
has active quiz
JAMA Cardiol. 2017;2(9):1038-1039. doi:10.1001/jamacardio.2017.1979

A 35-year-old woman with a history of hypertension and chronic lymphocytic leukemia who underwent allogenic bone marrow transplant presents to an emergency department with shortness of breath and productive cough. What would you do next?

JAMA Cardiology Clinical Guidelines Synopsis

Guidelines Update on Indications for Transcatheter Aortic Valve Replacement

Abstract Full Text
JAMA Cardiol. 2017;2(9):1036-1037. doi:10.1001/jamacardio.2017.2546

This article summarizes the guideline updates on indications for transcatheter aortic valve replacement.

Comment & Response

The Controversial Epidemiology of Left Ventricular Dysfunction in Patients With Myotonic Dystrophy Type 1—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(9):1044-1045. doi:10.1001/jamacardio.2017.0859

The Controversial Epidemiology of Left Ventricular Dysfunction in Patients With Myotonic Dystrophy Type 1

Abstract Full Text
JAMA Cardiol. 2017;2(9):1044. doi:10.1001/jamacardio.2017.0927

Myocardial Fibrosis in Duchenne and Becker Muscular Dystrophy

Abstract Full Text
JAMA Cardiol. 2017;2(9):1045-1046. doi:10.1001/jamacardio.2017.1013

Myocardial Fibrosis in Duchenne and Becker Muscular Dystrophy—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(9):1046. doi:10.1001/jamacardio.2017.1048

Bicuspid Aortopathy: The Show Must Go On

Abstract Full Text
JAMA Cardiol. 2017;2(9):1047. doi:10.1001/jamacardio.2017.1269

Bicuspid Aortopathy—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(9):1047-1048. doi:10.1001/jamacardio.2017.1272

Cardiovascular Risk Prediction in Patients With Human Immunodeficiency Virus—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(9):1048-1049. doi:10.1001/jamacardio.2017.0649

Cardiovascular Risk Prediction in Patients With Human Immunodeficiency Virus

Abstract Full Text
JAMA Cardiol. 2017;2(9):1048. doi:10.1001/jamacardio.2017.0667

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention: Is Smoker’s Paradox in Play?

Abstract Full Text
JAMA Cardiol. 2017;2(9):1049-1050. doi:10.1001/jamacardio.2017.2468

Ischemic Postconditioning During Primary Percutaneous Coronary Intervention: Is Smoker’s Paradox in Play?—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(9):1050. doi:10.1001/jamacardio.2017.2481
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2017;2(9):934. doi:10.1001/jamacardio.2016.3665
×